Cyanotech Corporation (CYAN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 32 | 36 | 23 | 23 | 24 | 27 | 27 |
| Operating profit | $m | -1 | 1 | ||||||
| Net profit | $m | 0 | 1 | 2 | -3 | -5 | -3 | -1 | -0 |
| EPS reported | $ | -0.18 | -0.01 | ||||||
| Operating cashflow per share | $ | 0.03 | 0.02 | ||||||
| Capex per share | $ | 0.02 | 0.03 | ||||||
| FCF per share | $ | 0.01 | -0.01 | ||||||
| Free cash flow | $m | 0 | 0 | ||||||
| Net debt | $m | 8 | 10 | ||||||
| Book value equity | $m | 8 | 8 | ||||||
| Book value per share | $ | 1.05 | 1.10 | ||||||
| Number of shares | m | 7.3 | 7.27 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.29 | 0.31 | ||||||
| P/S LTM | x | 0.08 | 0.09 | ||||||
| P/FCF LTM | x | 23.81 | 6.07 | ||||||
| EV/EBITDA LTM | x | 9.90 | 4.08 | ||||||
| EV/Sales LTM | x | 0.49 | 0.51 | ||||||
| Earnings Yield LTM | % | -58.51% | -1.94% | ||||||
| FCF Yield | % | +4.20% | +16.49% | ||||||
| Quality | |||||||||
| ROE | % | -16.74% | -0.87% | ||||||
| ROIC | % | -2.98% | +3.21% | ||||||
| Operating margin | % | -2.16% | +2.28% | ||||||
| Gross margin | % | +32.62% | +35.41% | ||||||
| FCF/Sales | % | +0.35% | -0.30% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +9.80% | +18.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.01 | 0.04 | ||||||
| Net Debt/EBITDA | x | 8.23 | 3.04 | ||||||
| EBIT/Net interest | x | -0.82 | 0.89 | ||||||
| Net debt/market cap | % | +4.03% | +2.42% | ||||||
| Net debt/Equity | x | 1.05 | 1.29 | ||||||
| Gross debt/equity | x | 1.51 | 1.42 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free